New imaging trick could tame radioactive cancer therapy
NCT ID NCT06122610
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 1 study tested whether a PET scan using 64Cu-DOTATATE (Detectnet) can help doctors plan safer doses of Lutathera therapy for people with neuroendocrine tumors. Four participants received both standard Lutathera treatment and extra PET/CT and SPECT/CT scans to compare how well the PET scan predicted radiation doses to tumors and healthy organs. The goal is to reduce side effects by personalizing treatment based on each patient's unique radiation exposure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 64Cu-DOTATATE (Detectnet) and 177Lu-DOTATATE (Lutathera)
- What this could lead to
- If successful, this approach could make Lutathera therapy safer by using a PET scan to better predict radiation doses to tumors and healthy organs.
- What could go wrong
- This was a very small, early-phase study with only 4 participants, so results may not apply broadly. The method is still experimental and not yet proven to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin - Madison
Madison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial